492. Epidemiology of admissions with influenza and the impact of underlying patient characteristics on the risk of admission with influenza during the 2013/14 season in the GIHSN participating sites
Session: Poster Abstract Session: Respiratory Infections: Influenza
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • IDWeek 492 GIHSN 2013 2014 EPI.ppt.pdf (2.1 MB)
  • Background:

    This was a multicentric study performed by the Global Influenza Hospital Surveillance Network (GIHSN). A total of 9,507 consecutive eligible admissions were screened for inclusion in 19 hospitals in Russia, Turkey, China and Spain, following a prospective, active surveillance, approach aimed to describe the epidemiology of admissions with influenza.

    Methods:

    Epidemiological data was collected in consecutive admissions using a common case definition. Influenza was confirmed by RT-PCR. We used multivariate logistic regression models to estimate influenza admission adjusted odds ratios (aOR).

    Results:

    We included 5,303 admissions, 1086 were influenza positive: 534, A(H3N2),  362, A(H1N1), 130, B Yamagata lineage, 3, B Victoria, 40 and 18, A and B, were not subtyped.

    Patients with cardiovascular disease aOR, 1.6 (1.3 to 2), asthma, 2.3 (1.7 to 3.0), immunosuppression, 2.3  (1.2 to 4.1), renal disease, 2.1 (1.5 to 3.0), liver disease, 1.9 (1.2 to 3.2), autoimmune disease, 3.9 (1.6 to 5.6), and pregnancy, 3.8 (2.5 to 5.9) were at an increased risk regardless of influenza virus. For chronic obstructive pulmonary disease, 2.6(1.9 to 3.6), diabetes, 3.7(2.6 to 5.3), and obesity, 3.1 (2.2-4.4), the risk of severe disease was preferentially related to A(H1N1)pdm. Sixty percent of influenza admissions were in patients with no comorbidity. We observed a non significant trend for influenza A(H1N1)pdm to increase the need of intensive care and for A(H3N2) the risk of in-hospital death. Respiratory failure was more common in admissions with A(H3N2). Influenza vaccination, 0.6(0.4-0.8) lowered the risk of confirmed influenza.

    Conclusion:

    Influenza was associated with disease needing admission in person with and without risk factors. Underlying comorbidity increased the risk of influenza and pregnancy was and outstanding risk factor. Our results support influenza vaccination as a risk reducing measure.

    Joan Puig-Barberŕ, MD, MPH, PhD1, Angels Natividad-Sancho, PhD1, Svetlana Trushakova, MD PhD2, Anna Sominina, Prof.3, Maria Pisareva, PhD3, Meral A.Ciblak, MD4, Selim Badur, Prof.4, Hongjie Yu, Dr. , MD, MPH5, Benjamin J.Cowling, BSc, PHD6, Clotilde El Guerche-Séblain, MSc.7, Ainara Mira-Iglesias, MSc.1, Lidiya Kisteneva, MD2, Kirill Stolyarov, BIT3, Kubra Yurtcu, MSc.4, Luzhao Feng, MD5 and Elena Burtseva, MD2, (1)Fundación para el Fomento de la investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain, (2)D.I. Ivanovsky Institute of Virology FGBC “N.F. Gamaleya FRCEM” Ministry of Health of Russian Federation, Moscow, Russia, (3)Research Institute of Influenza, Saint Petersburg, Russia, (4)National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, (5)Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China, (6)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, (7)Sanofi Pasteur, Lyon, France

    Disclosures:

    J. Puig-Barberŕ, Sanofi Pasteur Institution: funding for the study , Research support

    A. Natividad-Sancho, Sanofi Pasteur Institution: funding for the study , Research support

    S. Trushakova, Sanofi Pasteur Institution: funding for the study , Research support

    A. Sominina, Sanofi Pasteur Institution: funding for the study , Research support

    M. Pisareva, Sanofi Pasteur Institution: funding for the study , Research support

    M. A.Ciblak, Sanofi Pasteur Institution: funding for the study , Research support

    S. Badur, Sanofi Pasteur Institution: funding for the study , Research support

    H. Yu, Sanofi Pasteur Institution: funding for the study , Research support

    B. J.Cowling, Sanofi Pasteur Institution: funding for the study , Research support

    C. El Guerche-Séblain, Sanofi Pasteur Institution: funding for the study , Research support

    A. Mira-Iglesias, Sanofi Pasteur Institution: funding for the study , Research support

    L. Kisteneva, Sanofi Pasteur Institution: funding for the study , Research support

    K. Stolyarov, Sanofi Pasteur Institution: funding for the study , Research support

    K. Yurtcu, Sanofi Pasteur Institution: funding for the study , Research support

    L. Feng, Sanofi Pasteur Institution: funding for the study , Research support

    E. Burtseva, Sanofi Pasteur Institution: funding for the study , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.